ELOVL1 and X-linked adrenoleukodystrophy: To explore the therapeutic potential of this pathway, we employed the preclinically validated ELOVL1 inhibitor compound (22) that was originally developed in the context of X-linked adrenoleukodystrophy (X-ALD)24,25.